INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
Sign Up to like & getrecommendations! Published in 2022 at "Pulmonary Circulation"
DOI: 10.1002/pul2.12119
Abstract: Abstract The INSPIRE trial was a Phase 3, open‐label, multicenter trial (LTI‐301) that enrolled patients with pulmonary arterial hypertension (PAH) ≥ 18 years of age who transitioned to Yutrepia from nebulized treprostinil (Transition) or added Yutrepia to… read more here.
Keywords: safety; hypertension pah; arterial hypertension; trial ... See more keywords
Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway
Sign Up to like & getrecommendations! Published in 2019 at "Lung"
DOI: 10.1007/s00408-019-00283-8
Abstract: Epoprostenol, a synthetic prostaglandin I2 (PGI2) analog, has been the mainstay of treatment for severe pulmonary arterial hypertension (PAH) for the last two decades. Treprostinil, another synthetic prostaglandin analog, and selexipag, an oral selective Inositol… read more here.
Keywords: hypertension pah; thyroid dysfunction; prostacyclin; dysfunction ... See more keywords
COMORBIDITIES IN PULMONARY ARTERIAL HYPERTENSION (PAH): INSIGHTS FROM THE REAL-WORLD OPSUMIT® USERS (OPUS) REGISTRY
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)32728-5
Abstract: Many patients with PAH have comorbidities that may exclude them from clinical trials due to stringent inclusion criteria. The OPUS Registry ([NCT02126943][1]) is an ongoing, prospective, multicenter, US drug registry of patients newly treated with… read more here.
Keywords: comorbidities pulmonary; arterial hypertension; opus registry; hypertension pah ... See more keywords